By Colin Kellaher
AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.
AbbVie on Tuesday said the European Commission's nod makes Rinvoq the first and only oral advanced therapy approved in Europe for the inflammatory disease, which can cause headache, jaw pain and changes in vision, including sudden and permanent vision loss.
The North Chicago, Ill., biopharmaceutical company said the green light marks the eighth approved indication for Rinvoq in the European Union.
AbbVie in late January said it expects Rinvoq revenue to top $11 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 08, 2025 06:08 ET (10:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.